- MustGrow uses novel plant compounds to develop superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides
- The company leverages its innovative technology platform and the natural defensive mechanisms of the mustard plant for broad use in crop production and protection in order to provide consumers the healthy, safe and natural foods they demand
- The company has EPA approval for the granule form of its flagship product, TerraMG, and is currently waiting to receive approval for the liquid form in the United States and Canada
- MustGrow already has multiple projects in various stages of development, with a focus on all-natural and organic solutions for crops
- The liquid form of TerraMG has the potential for multiple applications, thus significantly enhancing the company’s IP position
- MustGrow is focused on the disruption of the global pesticide market, which totals $65 billion, while testing multiple applications of TerraMG and other products in significant markets
- The company has 37 million shares outstanding; management and advisors own 22%
MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, including fruits and vegetables. The company uses novel compounds from the mustard plant to provide superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides. Management & advisors own 22% of the company’s 37 million shares outstanding.
Leveraging its innovative platform, MustGrow effectively extracts the natural defense mechanisms of the mustard seed for broad use in crop production and protection. The company uses components of mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and…
NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.